Karessa's licence reinforced through patent granted in South Korea
A recently granted patent in South Korea has reinforced Karessa's licence in the field of erectile dysfunction. This entails recognition of Karessa's technical platform as well as sole rights to the company's products on the large and growing South Korean market.
Karessa's solution comprises a unique concept, combining the company's patented drug delivery platform with clinically tested and proven substances (e.g. Sildenafil and Tadalafil). This combination is creating major patient benefits in the form of fast and reliable effects. With the approval from the South Korean patent office, the patent has now been approved on ten markets. The patent protection in South Korea will apply until 22 December 2026.
"The fact that the patent has been granted on a large and expanding medicinal products market like South Korea is recognition of Karessa's technical platform. It is confirmation that our technology is unique and is providing a solution to a problem on the market," says Torbjörn Kemper, CEO of Karessa.
The South Korean medicinal products industry was worth approximately SEK 115 billion in 2013, according to a report by the Swedish Agency for Growth Policy Analysis (source: Hänt i världen, spring 2014). The country has invested heavily in drug development, which is considered to be a strategically important sector that is growing rapidly. The patent that has been granted offers considerable future opportunities for Karessa in South Korea.
"South Korea is a very interesting market, and the patent means that we have sole rights to our products. The investments that are being made in the medicinal products industry in the country can also entail opportunities for us, for example in the form of future collaborations," says Torbjörn Kemper.
The patent on which Karessa's technology is based is valid until 2026 and has been approved on a number of major markets, setting the stage for global distribution. The patent applications cover a total of 42 countries, including the EU (see the table below). In addition to South Korea, patent applications have to date been approved in Sweden, the USA (Notice of Allowance), China, Russia, Japan, Australia, New Zealand, South Africa and Israel. Karessa's licence for the invention applies to the whole world.
Torbjörn Kemper, CEO
CEO
torbjorn.kemper@karessa.se
+46 (0)08-768 22 33
About Karessa Pharma AB
Karessa Pharma AB is developing and commercialising the next generation of medicinal products to treat erectile dysfunction. Karessa's concept is based on a patented drug delivery film, which is combined with clinically tested and proven active substances. This combination results in a medicinal product that delivers both a direct and reliable effect. www.karessa.se
Tags: